Action Eli Lilly - LLY

Rendering Error

Discussions et idées de trading en temps réel : négociez en toute confiance avec notre puissante plateforme.

Premium

Dernier

34,15

Prix Achat

33,32

Prix Vente

34,43

Volume échangé

75 140

33,18 Fourchette du Jour 34,10

0,00 Plage de 52 semaines 0,00

Clôture Veille

33,62

Ouverture

33,41

Dernière Transaction

34.1

Dernière heure de transaction

Volume moyen (3 m)

Volume financier

VWAP

Lilly to participate in Leerink Partners Global Healthcare Conference

Lilly to participate in Leerink Partners Global Healthcare Conference PR Newswire INDIANAPOLIS, Feb. 28, 2025...

Lilly's Jaypirca (pirtobrutinib) recommended by CHMP for approval in the European Union for adults with relapsed or refractory chronic lymphocytic leukemia (CLL) previously treated with a BTK inhibitor

Lilly's Jaypirca (pirtobrutinib) recommended by CHMP for approval in the European Union for adults with...

Form 4 - Statement of changes in beneficial ownership of securities

Lilly plans to more than double U.S. manufacturing investment since 2020 exceeding $50 billion

Lilly plans to more than double U.S. manufacturing investment since 2020 exceeding $50 billion PR...

Form 4 - Statement of changes in beneficial ownership of securities

Form 144 - Report of proposed sale of securities

Organovo’s FXR Program, including FXR314, to Be Acquired by Eli Lilly and Company

SAN DIEGO, Feb. 25, 2025 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq:ONVO) (“Organovo” or the...

Lilly launches additional Zepbound vial doses and offers new savings for self-pay patients

Lilly launches additional Zepbound vial doses and offers new savings for self-pay patients PR...

Form 4 - Statement of changes in beneficial ownership of securities

Période	Variation	Variation %	Ouver.	Haut	Bas	Moyenne Vol. Quot.	VWAP
1	0	0	0	0	0	0	0	DR
4	0	0	0	0	0	0	0	DR
12	0	0	0	0	0	0	0	DR
26	0	0	0	0	0	0	0	DR
52	0	0	0	0	0	0	0	DR
156	0	0	0	0	0	0	0	DR
260	0	0	0	0	0	0	0	DR

LLY - Frequently Asked Questions (FAQ)

What is the current Eli Lilly share price?

The current share price of Eli Lilly is $ 34,15

What is the 1 year trading range for Eli Lilly share price?

Eli Lilly has traded in the range of $ 0,00 to $ 0,00 during the past year

Volume
% Gagnants
% Perdants

Symbole	Prix	Vol.
IBERIberAmerican Lithium Corp	$ 0,04 (14,29%)	39,4k
CBSTCannabist Company Holdings Inc	$ 0,09 (12,50%)	517,09k
ALGOLight AI Inc	0,74 (12,12%)	426,52k
MLMMcfarlane Lake Mining Limited	$ 0,05 (11,11%)	1,18M
DEFIValour Inc	$ 3,40 (6,92%)	5,51M
INXDINX Digital Company Inc	$ 0,04 (-33,33%)	163k
GRAMGold Flora Corporation	$ 0,04 (-20,00%)	1,84k
CDMNCanadian Manganese Company Inc	$ 0,02 (-20,00%)	524,03k
DMETDenarius Metals Corp	$ 0,56 (-17,65%)	98,32k
VRNOVerano Holdings Corp	$ 1,18 (-11,28%)	412,49k
DEFIValour Inc	$ 3,40 (6,92%)	5,51M
MLMMcfarlane Lake Mining Limited	$ 0,05 (11,11%)	1,18M
CDMNCanadian Manganese Company Inc	$ 0,02 (-20,00%)	524,03k
CBSTCannabist Company Holdings Inc	$ 0,09 (12,50%)	517,09k
BCBNBase Carbon Inc	$ 0,395 (-1,25%)	466,36k

Forums

Afficher les forums

Aucune Discussion Trouvée

Ajouter une Discussion

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Eli Lilly and Company (LLY)

Discussions et idées de trading en temps réel : négociez en toute confiance avec notre puissante plateforme.

Statistiques et détails clés

LLY Dernières nouvelles

Lilly to participate in Leerink Partners Global Healthcare Conference

Lilly's Jaypirca (pirtobrutinib) recommended by CHMP for approval in the European Union for adults with relapsed or refractory chronic lymphocytic leukemia (CLL) previously treated with a BTK inhibitor

Form 4 - Statement of changes in beneficial ownership of securities

Lilly plans to more than double U.S. manufacturing investment since 2020 exceeding $50 billion

Form 4 - Statement of changes in beneficial ownership of securities

Form 144 - Report of proposed sale of securities

Organovo’s FXR Program, including FXR314, to Be Acquired by Eli Lilly and Company

Lilly launches additional Zepbound vial doses and offers new savings for self-pay patients

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Lilly to participate in Leerink Partners Global Healthcare Conference

Lilly's Jaypirca (pirtobrutinib) recommended by CHMP for approval in the European Union for adults with relapsed or refractory chronic lymphocytic leukemia (CLL) previously treated with a BTK inhibitor

Form 4 - Statement of changes in beneficial ownership of securities

Lilly plans to more than double U.S. manufacturing investment since 2020 exceeding $50 billion

Form 4 - Statement of changes in beneficial ownership of securities

Form 144 - Report of proposed sale of securities

Organovo’s FXR Program, including FXR314, to Be Acquired by Eli Lilly and Company

Lilly launches additional Zepbound vial doses and offers new savings for self-pay patients

LLY - Frequently Asked Questions (FAQ)

Moteurs

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Période	Variation	Variation %	Ouver.	Haut	Bas	Moyenne Vol. Quot.	VWAP
1	0	0	0	0	0	0	0	DR
4	0	0	0	0	0	0	0	DR
12	0	0	0	0	0	0	0	DR
26	0	0	0	0	0	0	0	DR
52	0	0	0	0	0	0	0	DR
156	0	0	0	0	0	0	0	DR
260	0	0	0	0	0	0	0	DR

Période	Variation	Variation %	Ouver.	Haut	Bas	Moyenne Vol. Quot.	VWAP
1	0	0	0	0	0	0	0	DR
4	0	0	0	0	0	0	0	DR
12	0	0	0	0	0	0	0	DR
26	0	0	0	0	0	0	0	DR
52	0	0	0	0	0	0	0	DR
156	0	0	0	0	0	0	0	DR
260	0	0	0	0	0	0	0	DR

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Eli Lilly and Company (LLY) Cours

Eli Lilly and Company (LLY)

Discussions et idées de trading en temps réel : négociez en toute confiance avec notre puissante plateforme.

Statistiques et détails clés

LLY Dernières nouvelles

Lilly to participate in Leerink Partners Global Healthcare Conference

Lilly's Jaypirca (pirtobrutinib) recommended by CHMP for approval in the European Union for adults with relapsed or refractory chronic lymphocytic leukemia (CLL) previously treated with a BTK inhibitor

Form 4 - Statement of changes in beneficial ownership of securities

Lilly plans to more than double U.S. manufacturing investment since 2020 exceeding $50 billion

Form 4 - Statement of changes in beneficial ownership of securities

Form 144 - Report of proposed sale of securities

Organovo’s FXR Program, including FXR314, to Be Acquired by Eli Lilly and Company

Lilly launches additional Zepbound vial doses and offers new savings for self-pay patients

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Lilly to participate in Leerink Partners Global Healthcare Conference

Lilly's Jaypirca (pirtobrutinib) recommended by CHMP for approval in the European Union for adults with relapsed or refractory chronic lymphocytic leukemia (CLL) previously treated with a BTK inhibitor

Form 4 - Statement of changes in beneficial ownership of securities

Lilly plans to more than double U.S. manufacturing investment since 2020 exceeding $50 billion

Form 4 - Statement of changes in beneficial ownership of securities

Form 144 - Report of proposed sale of securities

Organovo’s FXR Program, including FXR314, to Be Acquired by Eli Lilly and Company

Lilly launches additional Zepbound vial doses and offers new savings for self-pay patients

LLY - Frequently Asked Questions (FAQ)

Moteurs

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Supprimer les publicités

Période	Variation	Variation %	Ouver.	Haut	Bas	Moyenne Vol. Quot.	VWAP
1	0	0	0	0	0	0	0	DR
4	0	0	0	0	0	0	0	DR
12	0	0	0	0	0	0	0	DR
26	0	0	0	0	0	0	0	DR
52	0	0	0	0	0	0	0	DR
156	0	0	0	0	0	0	0	DR
260	0	0	0	0	0	0	0	DR